• Non ci sono risultati.

ISSI Team “Vesta, the key to the origins of the Solar System”, and the Dawn Team

N/A
N/A
Protected

Academic year: 2022

Condividi "ISSI Team “Vesta, the key to the origins of the Solar System”, and the Dawn Team"

Copied!
1
0
0

Testo completo

(1)

Mem. S.A.It. Vol. 87, 202

SAIt 2016 c Memorie

della

Vesta as a geophysical laboratory for studying impact contamination

D. Turrini,

ISSI Team “Vesta, the key to the origins of the Solar System”, and the Dawn Team

INAF-IAPS, Istituto di Astrofisica e Planetologia Spaziali, Area di Ricerca di Tor Vergata, via Fosso del Cavaliere, 100, 00133, Rome, Italy

Abstract.

The NASA mission Dawn recently completed its investigation of Vesta (Russell et al. 2012) and left the asteroid leading for its second target, Ceres. Among the first results of the Dawn mission were the confirmation of the link between the bulk of the Howardite-Eucrite-Diogenite (HED) meteorites and Vesta (De Sanctis et al. 2012a; Prettyman et al. 2012), and the detection of the presence of dark material on the surface of the asteroid and in buried veneers exposed in the walls of craters (McCord et al. 2012). The Vesta-HED link suggests that the dark material is likely carbonaceous in nature (McCord et al. 2012; Reddy et al. 2012; Turrini et al. 2014). In close association to the dark material, the instruments on-board the Dawn spacecraft also revealed the presence of OH and H-rich material (De Sanctis et al. 2012b; Prettyman et al. 2012). In this talk I will discuss the role of impacts in delivering exogenous, volatile-rich material to Vesta, how the same impacts affected the vestan surface in terms of erosion, crater saturation and ejecta blanketing, and how the results obtained with the model developed to study the dark material can be applied to identify the best tracers for other kind of contaminants (Turrini et al. 2014).

References

De Sanctis, M. C., Ammannito, E., Capria, M. T., et al. 2012, Science, 336, 697 De Sanctis, M. C., Combe, J.-P., Ammannito, E., et al. 2012, ApJ, 758, L36 McCord, T. B., Li, J.-Y., Combe, J.-P., et al. 2012, Nature, 491, 83

Prettyman, T. H., Mittlefehldt, D. W., Yamashita, N., et al. 2012, Science, 338, 242 Reddy, V., Le Corre, L., O’Brien, D. P., et al. 2012, Icarus, 221, 544

Russell, C. T., Raymond, C. A., Coradini, A., et al. 2012, Science, 336, 684

Turrini, D., Combe, J.-P., McCord, T. B., et al. 2014, Icarus, 240, 86

Riferimenti

Documenti correlati

ONCOLOGIA MEDICA REGIONE LAZIO. 10

• Sanitari: gestione delle nuove tossicità e degli effetti collaterali a lungo termine, esiti della chirurgia e della radioterapia.

NUOVI BIOMARCATORI di MEDICINA NUCLEARE.. Le associazioni

In ottemperanza alla normativa ECM ed al principio di trasparenza delle fonti di finanziamento e dei rapporti con soggetti portatori di interessi commerciali in campo

• LBA7_PR - BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk

 ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND TARGET THERAPY (BRIM8 and COMBI-AD trials)?. ….the

LBA31 STAMPEDE: Abi or Doc – directly randomised data -No difference in OSS, SSE for ADT+Abi vs ADT+Doc. - Different mechanism of action , side effect profile, treatment duration

Among patients with metastatic HER2-negative BC and a germline BRCA1/2 mutation in the OlympiAD study, the objective response rate with olaparib tablet monotherapy was double that